Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seer, Inc. - Class A Common Stock (NQ: SEER )

2.210 -0.040 (-1.78%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 142,824
Open 2.220
Bid (Size) 2.210 (2)
Ask (Size) 2.580 (5)
Prev. Close 2.250
Today's Range 2.210 - 2.280
52wk Range 1.510 - 2.625
Shares Outstanding 65,088,575
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
Attributes 2,440% revenue growth to increased adoption of its Proteograph™ Product Suite and exciting discoveries made by Seer customers across multiple areas of biology and disease 
From Seer, Inc.
Via GlobeNewswire
Seer to Participate in Upcoming November Investor Conferences
From Seer, Inc.
Via GlobeNewswire

Performance

YTD
+13.92%
+13.92%
1 Month
-7.14%
-7.14%
3 Month
+27.01%
+27.01%
6 Month
+30.00%
+30.00%
1 Year
+22.78%
+22.78%

More News

Read More
Seer Reports Third Quarter 2024 Financial Results
From Seer, Inc.
Via GlobeNewswire
Recap: Seer Q4 Earnings
Via Benzinga
Earnings Scheduled For February 29, 2024
Via Benzinga
Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific
From Seer, Inc.
Via GlobeNewswire
Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer’s, Lung Cancer, and More at ASHG 2024
From Seer, Inc.
Via GlobeNewswire
Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer’s, Population Health, and Xenotransplantation at HUPO 2024
From Seer, Inc.
Via GlobeNewswire
Seer to Report Third Quarter 2024 Financial Results on November 6, 2024
From Seer, Inc.
Via GlobeNewswire
Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Seer, Inc.
Via GlobeNewswire
Seer Appoints Nicolas Roelofs to its Board of Directors
From Seer, Inc.
Via GlobeNewswire
Seer to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Seer, Inc.
Via GlobeNewswire
SEER Stock Earnings: Seer Beats EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Seer Reports Second Quarter 2024 Financial Results
From Seer, Inc.
Via GlobeNewswire
Seer to Report Second Quarter 2024 Financial Results on August 8, 2024
From Seer, Inc.
Via GlobeNewswire
Seer Proteograph™ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery
From Seer, Inc.
Via GlobeNewswire
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study
From Seer, Inc.
Via GlobeNewswire
SEER Stock Earnings: Seer Meets EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Seer Reports First Quarter 2024 Financial Results
From Seer, Inc.
Via GlobeNewswire
Seer Launches New Technology Access Center in Europe to Expand Accessibility to Unbiased Proteomic Solutions
From Seer, Inc.
Via GlobeNewswire
Seer to Report First Quarter 2024 Financial Results on May 8, 2024
From Seer, Inc.
Via GlobeNewswire
Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook
From Seer, Inc.
Via GlobeNewswire
Seer to Participate in the TD Cowen 44th Annual Health Care Conference
From Seer, Inc.
Via GlobeNewswire
Zoom Video And 2 Other Stocks Insiders Are Selling
Via Benzinga
Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery
From Seer, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.